[graphic-home]
Welcome to Syenza
Innovative healthcare technologies improve health, when accessible!
A future of vibrant health awaits, but access barriers are complex and seem insurmountable. Syenza advances access with our HEOR, Global Market Access, and Dynamic Intelligence scientific services for Pharmaceutical, Medtech, and Biotech businesses. Simply put, value science is how we accelerate access to innovations that improve health.
Health economic evaluations – Syenza News
- EU Launches Joint Scientific Consultations to Enhance Health Technology Assessment January 14, 2026Are your clinical studies ready for EU-wide HTA alignment? The European Commission has opened the first 2026 submission window for Joint Scientific Consultations (Jan 7–Feb 4, 2026) — a free opportunity to get early HTA input (including parallel EMA coordination) that helps design studies fit for Joint Clinical Assessments and smoother market access. Aligning evidence […]João L. Carapinha
- NICE Endorses Obecabtagene Autoleucel Therapy for Adult Relapsed B-Cell Leukaemia November 25, 2025Could a UK-developed CAR T therapy significantly improve survival for adults with relapsed B‑cell ALL? 🧬 NICE has recommended obecabtagene autoleucel for adults aged 26+ (subject to a commercial deal), finding improved event‑free and overall survival versus blinatumomab, inotuzumab and ponatinib and cost‑effectiveness within NHS thresholds — though it’s not recommended for 18–25s due to […]João L. Carapinha
- Health Investment Returns: Harnessing Health as a Strategic Economic Asset November 18, 2025Can health be a nation's most strategic asset? 💡📈 EFPIA’s guest analysis reframes health spending as high-return investment—showing how targeted innovation and earlier care (notably for HER2+ breast cancer) can reduce disease-driven productivity losses, unlock trillions in GDP, and deliver up to $4 back per $1 spent. It also outlines HEOR methods and policy shifts […]João L. Carapinha
